JAK2_V617F by qPCR
Janus Kinase 2; V617F; JAK2 Exon 14; Janus nonreceptor tyrosine kinase 2
- Tech Only CPT 81270
- Tech Pro CPT NA
- PowerPath Code JAK2 PCR
- Schedule Monday-Friday (Variable)
- Turn Around Time 4-7 Days
- Disease State Chronic myeloproliferative disorder
- Methodology Real-time Polymerase Chain Reaction (qPCR)-based analysis of Exon 14 of the JAK2 gene.
Organs
Specimen Requirements
Minimum of 1 mL whole blood in a purple (EDTA) or pink top tube (EDTA); minimum of 1 mL of bone marrow aspirate in a purple, pink, or green (heparin) top tube.
Clinical Significance
The V617F mutation in the Janus nonreceptor tyrosine kinase 2 (JAK2) gene has been reported in a significant proportion of patients with chronic myeloproliferative disorders (MPDs). The somatic mutation occurs in the transformed hematopoietic precursor and has been identified in 65-97% of polycythemia vera, 23-57% of essential thrombocythemia, and 35-57% of myelofibrosis specimens.
Required Patient Info
Copy of the referring client's requisition form to accompany specimen.
Storage and Transportation
Refrigerated: 5 days; ambient (room temperature): 3 days; specimen must be received by laboratory within 7-days of collection.
Cause for Rejection
Frozen specimen; clotted or grossly hemolyzed specimens; serum; specimens without 2 patient identifiers; serum or plasma, aliquots (previously open containers); specimen that were received >7-days after collection.
Retention
2 years DNA and raw data; whole blood and bone marrow - 1 week.
Comments
This test was developed and its performance characteristics determined by CellNetix Labs LLC. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. CellNetix is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.